Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Proof of Concept, Randomized, Placebo-Controlled, Parallel Group Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination on Atrial Fibrillation Burden in Subjects With Paroxysmal Atrial Fibrillation.

Trial Profile

A Phase 2, Proof of Concept, Randomized, Placebo-Controlled, Parallel Group Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination on Atrial Fibrillation Burden in Subjects With Paroxysmal Atrial Fibrillation.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 09 Nov 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dronedarone/ranolazine (Primary) ; Dronedarone; Ranolazine
  • Indications Paroxysmal atrial fibrillation
  • Focus Proof of concept; Therapeutic Use
  • Acronyms HARMONY
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 26 May 2014 Status changed from active, no longer recruiting to completed, according to a Gilead Sciences media release.
    • 10 May 2014 Results were presented during a late-breaking clinical trials session at the annual meeting of the Heart Rhythm Society and reported in a Gilead Sciences media release.
    • 27 Jan 2014 New source identified and integrated; United Kingdom Clinical Research Network.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top